Premium
Cyclophosphamide therapy and interstitial pulmonary fibrosis
Author(s) -
Patel Ashok R.,
Shah Prabodh C.,
Rhee Hwaja L.,
Sassoon Harry,
Rao Koduri P.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197610)38:4<1542::aid-cncr2820380416>3.0.co;2-r
Subject(s) - medicine , cyclophosphamide , prednisone , pulmonary fibrosis , discontinuation , pulmonary toxicity , interstitial lung disease , tachypnea , lung , chemotherapy , tachycardia
Interstitial pneumonia and pulmonary fibrosis developed in a 72‐year‐old man during therapy with cyclophosphamide, vincristine, and prednisone. After extensive investigations, including an open lung biopsy, cyclophosphamide appeared to be the cause of the pulmonary disease. Complete disappearance of tachypnea and the pulmonary infiltrates occurred after the discontinuation of cyclophosphamide and the institution of prednisone therapy. We concluded that the diffuse pulmonary disease in this patient was a result of cyclophosphamide therapy. The clinical and pathologic findings in this case and a review of the literature of cyclophosphamide pulmonary toxicity are reported.